Want to see MAZE full AI Analyst Report?
MAZE Stock Chart & Stats
$29.58
$1.05(3.79%)
At close: 4:00 PM EDT
$29.58
$1.05(3.79%)
Day’s Range― - ―
52-Week Range$21.95 - $53.65
Previous CloseN/A
Volume102.86K
Average Volume (3M)705.88K
Market Cap
$1.47B
Enterprise Value$1.41B
Total Cash (Recent Filing)$411.09M
Total Debt (Recent Filing)$60.42M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Nov 05, 2026EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.74
Shares Outstanding55,549,168
10 Day Avg. Volume1,113,143
30 Day Avg. Volume705,884
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-15.79
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue70.49
Enterprise Value/Gross Profit73.98
Enterprise Value/Ebitda-10.82
Forecast
1Y Price Target
$61.43Price Target Upside107.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.78
Revenue Forecast (FY)$20.00M
Bulls Say, Bears Say
Bulls Say
Low Balance-sheet LeverageEquity of $453.1M and low debt relative to assets provide a meaningful capital base for continued development, while debt-to-equity of about 0.13 limits balance-sheet leverage. This cushion can preserve flexibility as Maze funds clinical programs.
High Gross MarginAn approximately 95% gross margin indicates that reported revenue has strong gross economics before operating expenses. If Maze converts its pipeline into recurring commercial sales, this profile could support attractive incremental economics, although current revenue remains inconsistent.
Strengthened Board ExpertiseThe addition of directors with clinical, academic and biopharmaceutical experience strengthens governance as Maze advances its kidney and metabolic programs. Their committee roles and sector expertise can improve oversight of development priorities and upcoming Phase 2 milestones.
Bears Say
Sustained Cash BurnLarge negative operating and free cash flow show that Maze is consuming substantial cash to operate and develop its programs. Continued outflows may increase future funding needs, reduce financial flexibility, and make progress dependent on maintaining adequate capital resources.
Deep Operating LossesThe sizable net loss and negative return on equity indicate that Maze’s current capital base is not yet producing earnings power. Operating costs materially exceed gross profit, so profitability depends on future pipeline progress and a meaningful improvement in revenue generation.
Inconsistent Revenue BaseThe sharp swings in reported revenue demonstrate limited consistency in the company’s current revenue base. That volatility makes operating performance harder to sustain and leaves Maze primarily reliant on advancing investigational therapies before durable commercial revenue can develop.
Maze Therapeutics, Inc. News
MAZE FAQ
What was Maze Therapeutics, Inc.’s price range in the past 12 months?
Maze Therapeutics, Inc. lowest stock price was $21.95 and its highest was $53.65 in the past 12 months.
What is Maze Therapeutics, Inc.’s market cap?
Maze Therapeutics, Inc.’s market cap is $1.47B.
When is Maze Therapeutics, Inc.’s upcoming earnings report date?
Maze Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 29 days.
How were Maze Therapeutics, Inc.’s earnings last quarter?
Maze Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.717 by -$0.043.
Is Maze Therapeutics, Inc. overvalued?
According to Wall Street analysts Maze Therapeutics, Inc.’s price is currently Undervalued.
Does Maze Therapeutics, Inc. pay dividends?
Maze Therapeutics, Inc. does not currently pay dividends.
What is Maze Therapeutics, Inc.’s EPS estimate?
Maze Therapeutics, Inc.’s EPS estimate is -0.76.
How many shares outstanding does Maze Therapeutics, Inc. have?
Maze Therapeutics, Inc. has 55,549,168 shares outstanding.
What happened to Maze Therapeutics, Inc.’s price movement after its last earnings report?
Maze Therapeutics, Inc. reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.717. Following the earnings report the stock price went up 0.806%.
Which hedge fund is a major shareholder of Maze Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MAZE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Maze Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.43 (107.67% Upside)
$61.43 (107.67% Upside)
Blogger Sentiment
Bullish
MAZE Sentiment 75%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
75.15%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
MAZE Stock 12 Month Forecast
Average Price Target
$61.43
▲(107.67% Upside)
Technical Analysis
Intellia Therapeutics
―
Damora Therapeutics
―
Recursion Pharmaceuticals
―
Ginkgo Bioworks Holdings
―
Generate Biomedicines, Inc.
―
Ownership Overview
10.93% Insiders
5.50% Mutual Funds
68.30% Other Institutional Investors
5.98% Public Companies and
Individual Investors